G

Genus

Global animal genetics and breeding technology

Key Account Manager

Full-TimeDeadline 9/11/27
€55k - €75k/yr+ Commission up to 30% + Company vehicle
Mid
Bachelor's
Remote in Ireland
RemoteMust reside in Ireland and have the right to work there; regular travel within Ireland and occasional international travel required.
Sales & Account ManagementAccount Management

About the job

Requirements
  • Proven success in business-to-business sales, key account management, or commercial relationship management within the pork industry.
  • Strong commercial judgment, with experience of growing accounts, negotiating agreements, and managing contracts.
  • Ability to build credibility and influence customers and stakeholders at different levels.
  • A consultative approach, with the curiosity to understand customer challenges and translate insight into practical commercial solutions.
  • Experience of budgeting, forecasting, and using data to support decisions.
  • Clear communication, presentation, and influencing skills.
  • Ability to work independently, manage changing priorities, and deliver commitments across a geographically dispersed customer base.
  • Confidence working collaboratively across functions, ideally within a matrix organisation.
  • Proficiency in Microsoft Office, particularly Excel and PowerPoint.
  • A bachelor's degree or equivalent relevant experience.
  • Comfort and experience working in a remote setting.
  • Ability to thrive as a self-starter and work autonomously.
Responsibilities
  • Build and deliver strategic account plans that support customer goals and PIC profit targets.
  • Identify and develop new business opportunities within the Irish market and existing customer base.
  • Grow sustainable revenue and profitability across assigned accounts and areas.
  • Lead the negotiation, renewal, and ongoing management of customer contracts, balancing commercial opportunity with appropriate risk management.
  • Establish trusted, long-term relationships with key customers and influential industry contacts.
  • Help customers realise the full value of genetic improvement through a consultative, insight-led approach.
  • Prepare and manage budgets, forecasts, and commercial plans for the area of responsibility.
  • Monitor market developments, customer needs, and competitor activity to inform commercial priorities.
  • Partner with Marketing, Supply Chain, Technical Services, Genetic Services, and Finance to deliver an effective customer experience and support strategic objectives across the United Kingdom, Ireland, and Europe.
  • Contribute to Northern European commercial strategy and support the Commercial Director with priority initiatives.
  • Travel regularly within Ireland, with occasional international travel.
Desired Qualifications
  • A qualification in agriculture, animal science, or a related discipline.

About the company

Genus is a global animal-genetics company focused on improving cattle and pig performance through breeding and genetic technologies. It operates two main units, ABS Global for bovine genetics and PIC for porcine genetics, offering breeding animals, reproduction services, and gene-editing and next-generation breeding tools. Its products work by combining genetics, reproductive biology, and data-driven selection to produce healthier herds, higher-quality food, and more efficient production. Genus differentiates itself through its global scale (operations in 30 countries and distribution to over 50 markets), its specialized units for cattle and pigs, and its integration of science with practical farming solutions. Its goal is to sustainably nourish the world by improving animal health, food quality, and the resilience of the global food system, while delivering value to customers and upholding ethical, collaborative values.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Basingstoke, United Kingdom

Founded

1933

Get referred to Genus

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Genus said 14 July 2026 FY26 results should beat consensus and cut leverage.
  • The Chinese porcine joint venture delivered about £111 million cash in FY26.
  • ABS posted double-digit profit growth in FY26, helped by the Value Acceleration Programme.

What critics are saying

  • North American PIC volumes weakened in FY26 from customer disease challenges.
  • Genus still depends on further approvals before selling PRRS-resistant pigs in Canada.
  • If EU and U.S. adoption stalls, PRRS-resistant pigs stay a stranded platform.

What makes Genus unique

  • PIC’s PRRS-resistant pigs won Canada approval on 23 January 2026.
  • Genus monetizes elite genetics through recurring royalties, not commodity livestock sales.
  • ABS and PIC combine bovine and porcine genetics across 100-plus countries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Parental Leave
  • Employee Stock Purchase Plan
  • Paid Holidays
  • Paid Vacation

Company News

Associated Press
Jan 23rd, 2026
Canada approves PRRSV-resistant pigs for food and feed to cut farm losses and antibiotic use

Canada has approved genetically engineered pigs resistant to porcine reproductive and respiratory syndrome viruses for use in food and feed. Health Canada and the Canadian Food Inspection Agency completed independent safety assessments following applications from Genus PLC and PIC Canada, concluding the pigs are as safe and nutritious as conventional pork. The approval addresses PRRSV, one of the most devastating virus classes affecting farmed pigs, which causes severe symptoms including breathing problems, fever and stillborn piglets. There are currently no effective treatments available. Genus PLC's PRRSV-resistant pigs are already approved in the US, Brazil, Colombia and the Dominican Republic. However, the company will not sell these pigs in Canada until receiving regulatory authorisation in other key markets. Canada's swine industry generated over $6.3 billion in farm cash receipts in 2024.

TipRanks
Oct 21st, 2024
Genus plc CFO to Retire, Successor Search Underway

Genus plc, a global leader in animal genetics, has announced the upcoming retirement of its Chief Financial Officer, Alison Henriksen, who will leave her role in July 2025 after five years with the company.

PharmiWeb
Sep 7th, 2023
Genus Plc Preliminary Results For The Year Ended 30 June 2023

SOLID PERFORMANCE AND GOOD STRATEGIC PROGRESSWEBCAST AVAILABLE AT 7:01AM GMT, 2.01 ESTLONDON--(BUSINESS WIRE)--Genus (LSE:GNS), a leading global animal genetics company, today announces its preliminary results for the year ended 30 June 2023. The full report has been made available on the investors section of the Genus plc website. The Company will discuss its corporate, operational and financial highlights in a pre-recorded webcast at 7:01 AM GMT, 2.01 EST.Commenting on the performance and outlook, Jorgen Kokke, Chief Executive Officer, said:“The Group achieved a strong operational performance despite ongoing challenging market conditions for producers in several important markets. Revenues grew in all regions and both PIC and ABS delivered profit growth. This also enabled us to deliver record adjusted EBITDA and good cashflow for the Group. Growth in R&D investments, primarily due to the strategically important gene editing work and expansion of PIC’s elite farms, as well as higher interest costs, resulted in adjusted profit before tax consistent with the prior year.“PIC’s performance was particularly impressive, achieving a record adjusted operating profit for the year

MarketWatch
Apr 3rd, 2023
Genus Names Jorgen Kokke as Chief Executive Officer Designate

Genus PLC said Monday that it has appointed Jorgen Kokke as chief executive officer designate, effective from May 2.

PharmiWeb
Sep 8th, 2022
Genus Plc Reports Preliminary Results For The Year Ended 30 June 2022

Continued Strategic Progress in Challenging Markets. Webcast Available at 7:01AM BST, 2.01 EDT